neo-811

Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform February 03, 2026 13:08 ET | Source:…

4 hours ago